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1. Introduction
  In recent years, the application of vascular endothelial 
growth factor (VEGF) gene therapy such as acute myocardial 
infarction and chronic myocardial ischemia, peripheral 
artery disease, gastric duodenal ulcer and other diseases, 
has become a hot research at home and abroad[1]. Green 
fluorescent protein (GFP) is a protein which comes from 
the jellyfish, and under certain excitation light shows 
green fluorescent[2]. Bone marrow mesenchymal stem cells 
(BMSCs) is a kind of adult stem cells, which has been widely 
used and investigated in both tissue engineering and the 
treatment of various diseases. This study was to discuss the 
role of bone marrow mesenchymal stem cells (BMSCs) in 
construction of vascularized engineered tissue.
2. Materials and methods
2.1. Experiment instruments and reagents
  PCR (Bio-Rad, USA); BIO-RAD Gel Doc XR + Gel 
imaging system (BIO-RAD, USA). 毩-minimal essential 
medium (Hyclone, USA), 0.25% Trypsin-EDTA (Gibco, 
USA); ShengGong primer synthesis (Shanghai); Total 
RNA extraction reagent (TaKaRa Biotechnology, Dalian); 
Lipofectamine transfectionTM 2000 kit (Invitrogen, 
USA); PrimeScript襅RT reagent Kit With gDNA Eraser 
(TaKaRa Biotechnology, Dalian); DNA Marker (TaKaRa 
Biotechnology, Dalian); 2暳Pfu PCR Master Mix (TIANGEN 
technology co., LTD., Beijing, China); PShuttle GFP-CMV (in 
this lab, preliminary build) AdEasy-1 system (Stratagene, 
USA), competent Escherichia coli (E. coli) DH5, restriction 
enzyme BamH栺, Xho栺, Hand 栿, EcoR栺and standard 
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DNA marker (Promega); VEGF antibody ((Bioss, China); DAB 
chromogenic reagent kit (Dako, USA).
 
2.2. Methods
2.2.1. Construction and identification of recombinant shuttle 
plasmid vectors
 hVEGF165 was amplified from pcDNA3. 1-VEGF165 
plasmid (sequenced to be correct), followed by agarose 
gel electrophoresis and purification. BamH栺 and Xho
栺 enzyme were used for recycling of PCR products and 
pShuttle GFP-double enzyme CMV, electrophoresis was 
performed with plastic recycling kit after purification at 
16 曟 by T4 DNA ligase connection over night. pShuttle GFP-
hVEGF165 recombinant plasmid was obtained. E. coli DH5 
alpha cells was transformed by calcium chloride method, 
and recombinant plasmid was screened by blue white spot 
screening. Plasmid was extracted by alkali decomposition 
method. Then it underwent double enzyme digestion by 
BamH栺 and Xho栺 and sequencing identification.
2.2.2. pAd-GFP-building and identification of hVEGF165 
recombinant plasmid
  pShuttle GFP-hVEGF165 recombinant plasmid was digested 
and linearized by Pme栺. pAdEasy-1 was transformed into 
the E. coli by hot shock method, and screened by Amp + 
resistance screening. BJ5183 competent bacterium (including 
pAdEasy-1) was transformed by electronic shock with 1 毺g 
linearized pShuttle GFP-hVEGF165 plasmid (2.2 kV, 2.2 ms), 
and then was screened by kanamycin resistance screening. 
Plasmid was extracted by alkali decomposition method, 
identified by BamH栺, Pac栺, respectively. Recombinant 
plasmid of pAd-GFP-hVEGF165, VEGF specific fragments 
were amplified by PCR, hVEGF165 gene sequence was 
detected, and positive clones were amplified largely.
2.2.3. Transfection of VEGF165 recombinant plasmid 
 With Pac栺 enzyme, pAd-GFP-hVEGF165 was digested 
and linearized, then was transfection into HEK 293T 
cells. Recombinant plasmid and empty vector plasmid 
were extracted, then was transfection into HEK 293T 
cells according to LipofectamineTM 2000 instructions. The 
expression of green fluorescent protein was observed at 24 h 
and 6 day.
2.2.4. Construction and identification of BMSCs 
  Upper and lower end of metaphysis was removed in adult 
rat, and bone marrow was mixed with 毩-MEM containing 
20% fetal bovine serum in petri dishes. It was blew and beat 
by a straw to make cells scattered and was incubated at 
37 曟, 5% CO2 and saturated humidity for normal pancreatic 
enzyme digestion. The 4th generation cells of BMSCs was 
taken and fixed with 4% paraformaldehyde for 2 h. It was 
washed by PBS, added with 3% H2O2 at room temperature 
for 20 min to inactivate endogenous peroxidase, then it was 
washed again with PBS. It was blocked by goat serum for 
1 h, with rat anti VEGF antibody as first antibody, biotin 
labeled goat anti mouse antibody as the second antibody. 
SH3 expression in transfected cells was detected by DAB 
chromogenic method.
2.2.5. Transfection of BMSCs by lipofection
  According to LipofectamineTM 2000 liposome transfection 
reagent instruction, 4th generation cells of BMSCs were 
digested by pancreatic enzyme, and then was counted. It 
was inoculated at 3暳10
4/mL to 24 hole plate. When fusion 
of cell growth was around 80%, plasmid DNA of pAd-
GFP-hVEGF165 diluted by OptiMEM襅栺 Medium and 
LipofectamineTM 2000 diluted by OptiMEM襅Medium was 
mixed, and incubated for 20 min; Mixture was added to each 
hole, and incubated at 37 曟 and 5% CO2, saturated humidity. 
After 6 h it was cultured by DMEM containing 10% FBS/F-12 
media, and then was screened and cultured.
2.2.6. RT-PCR for detecting hVEGF gene expression after 
transfection
  Total RNA of BMSCs was extracted after transfection, 
cDNA was obtained by reverse transcription. According to 
the instruction manual, 2暳Pfu PCR Master Mix was used 
to detect the expression of VEGF mRNA. Forward primer: 
5'- GGAGGGCAGAATCATCACGAAG-3', reverse primer: 
5'-CACACAGGATGGCTTGAAGATG-3'. Amplification 
length was 138 bp. Forward primer of毬-actin: 5'-
ACGGTCAGGTCATCACTATCG-3’, reverse primer: 5'-
GGCATAGAGGTCTTTACGGATG-3', amplification length 
was 155 bp. Image was obtained by BIO-RAD Gel Doc XR+ 
Gel imaging system. Transfected VEGF cells were identified 
by immunohistochemical assay.
3. Results
3.1. PCR identification of recombinant shuttle plasmid vector 
  Recombinant shuttle plasmid product was transformed into 
E. coli DH5 alpha, single colony was selected as a template 
to test strain. The results revealed hVEGF165 expression 
vector in same size (Figure 1).
Figure 1. Colony of recombinant shuttle plasmid vector by PCR.
3.2. Enzyme identification of recombinant shuttle plasmid 
vector
  It was digested by Hind 栿 and Xho栺, and then identified 
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by agarose gel electrophoresis and sequencing. Sequencing 
results showed that recombinant shuttle plasmid carrier was 
successfully established (Figure 2).
Figure 2. Recombinant shuttle plasmid vector sequence map.
3.3. Identification of recombinant plasmid pAdEasy-
hVEGF165
  The product of agarose gel electrophoresis was digested 
with Pac栺, and two fragments were obtained (Figure 3). 
It showed that recombinant plasmid was successfully 
established.
Marker   Vector
3 000 bp
2 000 bp
1 500 bp
1 000 bp
700 bp
500 bp
300 bp
100 bp
Figure 3. Detection of recombinant plasmid.
3.4. MRNA expression in HEK 293T cells 
  After transfection, total RNA of HEK 293T cells was 
detected by RT-PCR detection. It was found that VEGF165 
had high expression, but it was not expressed in empty 
transfection group (Figure 4).
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Figure 4. Expression of VEGF165. 
3.5. Expression of GFP in the HEK 293T cell
  24 h after transfection, cells showed green fluorescence 
expression (Figure 5a), and 6 days after transfection, all cells 
were positively expressed (Figure 5b).
Figure 5. Expression of green fluorescence after transfection (暳100).
A: after 24 h; B: after 6 days.
3.6. Identification of bone marrow mesenchymal cells
 
  Immunohistochemicalsaasy showed that SH3 had positive 
expression (Figure 6a). After mineralization and alizarin red 
staining, BMSCs positive staining was observed (Figure 6b).
Figure 6. BMSCs identification.
 A: SH3 immunohistochemical staining (暳400); B: Alizarin red staining 
(暳200).
3.7. hVEGF gene expression after transfection 
  After transfection, BMSCs group showed VEGF expression, 
and no expression in control group (Figure 7).
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Figure 7. hVEGF gene expression after transfection.
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3.8. BMSC VEGF protein expression after transfection
  After transfection, positive staining cells showed brown 
cytoplasm and nucleus, and transfection of the control group 
showed no positive staining (Figure 8).
Figure 8. BMSC VEGF protein expression after transfection.
A: transfection group; B: not transfection group. 
4. Discussion
   In gene therapy study, efficiency and feasibility of gene 
transfection should be observed and evaluated. Gene report 
is common detection method. Common genes in report such 
as beta x-gal enzyme gene (LacZ) and luciferase gene (Lux) 
gene, should interact with specific substrates to produce 
detectable signals. GFP expression system is able to detect 
transfection efficiency and fluorescence intensity at the 
same time. It is rapid, convenient and of great repeatability, 
and can be used in quantitative analysis. It is ideal mark for 
detecting gene and protein expression and localization of in 
cells and tissues, and has been widely used in gene therapy, 
drug screening, and researches of transgenic animals, etc[3].
  VEGF can carry signals by combining with specific 
receptors on the surface of the endothelial cells[4], so as 
to maintain normal blood vessels and integrity, increase 
vascular permeability, promote endothelial proliferation and 
angiogenesis. In recent years, studies have shown that VEGF 
protein injection or VEGF gene treatment in tissue repair 
and angiogenesis shows a good application prospect[5-7].
  Ectomesenchymal stem cells are derived from adult bone 
marrow pluripotent stem cells in the bone marrow, because 
of its strong ability of differentiation and self-renewal ability 
and are widely used in theoretical research. Bone marrow 
mesenchymal stem cells have great potential in genetically 
modified in the treatment. It can modify MSCs, make its 
over-expression to induce apoptosis ligand and cytokines, 
etc. then it can effectively treat glioma, colon and prostate 
cancer[8-11]. It has been reported in treatment of brain 
ischemia and neurodegenerative diseases[12-14].
  In conclusion, this study successfully constructed 
recombinant adenovirus vector of VEGF expressed in 
GFP and human, transformed VEGF into bone marrow 
mesenchymal stem cells with green fluorescent protein 
markers, and successfully constructed the VEGF-GFP-
BMSCs. It helps real-time tracking after VEGF modified 
BMSCs in the repair tissue damage, its role in the treatment 
of related diseases. It has potential application value and 
clinical significance.
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